Aficamten
Sponsors
Cytokinetics Inc., Cytokinetics, Corxel Pharmaceuticals, Oregon Health and Science University
Conditions
Healthy ParticipantsHypertrophic Cardiomyopathy (HCM)Obstructive Hypertrophic CardiomyopathyPediatricSYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHYSYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHYSymptomatic Non-Obstructive Hypertrophic CardiomyopathySymptomatic Obstructive Hypertrophic Cardiomyopathy
Phase 1
Phase 2
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Active, not recruitingNCT06412666
Start: 2024-05-29End: 2030-01-01Target: 65Updated: 2026-08-18
A Follow-Up, Open Label, Research Evaluation of Sustained Treatment with Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
RecruitingCTIS2023-508963-58-00
Start: 2022-01-31Target: 235Updated: 2025-08-14
A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled and Open-label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Not yet recruitingCTIS2024-511377-30-00
Target: 4Updated: 2024-12-02
Phase 3
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Active, not recruitingNCT06081894
Start: 2023-08-31End: 2026-10-01Target: 500Updated: 2026-08-05
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
CompletedNCT06116968
Start: 2023-11-14End: 2025-10-20Updated: 2026-01-21
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
CompletedCTIS2023-504809-37-00
Start: 2024-02-07End: 2025-02-14Target: 53Updated: 2025-02-14
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Active, not recruitingCTIS2023-505797-15-00
Start: 2024-09-13Target: 175Updated: 2025-10-14